Is Allakos Inc. (ALLK) a Buy, Sell, or Hold?
NASDAQ : ALLK
Allakos Inc.
$0.3291 USD
$0.0 (0.21%)
- Volume
- 1.31M
- Average Volume
- 1.16M
- Market Capitalization
- $29.74M
- P/E Ratio
- -0.25
- Dividend Yield
- 0.00%
- Price Target
- $109.50
- Year High
- $1.56
- Year Low
- $0.22
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $4.81
Company Overview
NASDAQ
Robert Alexander
Biotechnology
Healthcare
ALLK
131
US
USD
Liquidity Metrics
0.05
4.81
4.81
1.00
0.00
Sales & Valuation
-$
0.00
0.37
-0.32
-1.06
Profitability
-$1.3
-$115.82M
0.00%
0.00%
-93.54%
-119.89%
P/E Metrics
-0.25
0.00
0.00
Analyst Price Target & Rating
$109.50
$218.00
$1.00
0/5
11 Analysts
-99.70%
Financial Health Scores
-29.64
1/9
$54.01M
$59.54M
$4.08M
-$99.75M
Key Metrics (TTM)
$16.15M
0.00
-0.15
4.81
-93.54%
-140.27%
-396.35%
-315.18%
-259 days
Company Executives
| Name | Title |
|---|---|
| Baird Radford | Chief Financial Officer |
| Robert Alexander | Chair of the Board, Chief Executive Officer & Director |
| H. Baird Radford | Chief Financial Officer |
| Alan Chang | Director of Medical Affairs & Data Analytics |
| Adam L. Tomasi | President |
Poll Results
No votes yet today — be the first to share your view!
About Allakos Inc. (NASDAQ:ALLK) Stock
Allakos Inc. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing therapeutic agents. These treatments are designed to target specific immunomodulatory receptors on immune effector cells, addressing a spectrum of allergic, inflammatory, and proliferative conditions. The company's flagship investigational product is lirentelimab (AK002), a monoclonal antibody. This compound is currently undergoing a pivotal Phase III clinical trial for eosinophilic gastritis and/or duodenitis. It is also being evaluated in a Phase II/III study for eosinophilic esophagitis, and a Phase II trial for atopic dermatitis and chronic spontaneous urticaria. Furthermore, Allakos is exploring lirentelimab (AK002) for potential use in mast cell gastrointestinal disease, chronic urticaria, ... severe allergic conjunctivitis, and indolent systemic mastocytosis. In parallel, their pipeline includes AK006, another candidate being developed to tackle various allergic and inflammatory diseases. Established in 2012, Allakos Inc. operates from its headquarters located in Redwood City, California.
Frequently Asked Questions
-
What is the current Allakos Inc. (ALLK) stock price?
-
Allakos Inc.(NASDAQ:ALLK) stock price is $0.3291 in the last trading session. During the trading session, ALLK stock reached the peak price of $1.56 while $0.22 was the lowest point it dropped to. The percentage change in ALLK stock occurred in the recent session was 0.21% while the dollar amount for the price change in ALLK stock was $0.0.
-
ALLK's industry and sector of operation?
-
The NASDAQ listed ALLK is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of ALLK?
-
Baird Radford | Chief Financial Officer
Robert Alexander | Chair of the Board, Chief Executive Officer & Director
H. Baird Radford | Chief Financial Officer
Alan Chang | Director of Medical Affairs & Data Analytics
Adam L. Tomasi | President -
How many employees does ALLK have?
-
Number of ALLK employees currently stands at 131. ALLK operates from 975 Island Drive, San Carlos, CA 94065, US.
-
Link for ALLK official website?
-
Official Website of ALLK is: https://www.allakos.com
-
How do I contact ALLK?
-
ALLK could be contacted at phone #650 597 5002 and can also be accessed through its website. ALLK operates from 975 Island Drive, San Carlos, CA 94065, US.
-
How many shares of ALLK are traded daily?
-
The average number of ALLK shares traded daily for last 3 months was 1.16M.
-
What is the market cap of ALLK currently?
-
The market value of ALLK currently stands at $29.74M with its latest stock price at $0.3291